Dongkook stock gains 5.99 percent on overseas growth plans

Published on 10/07/2026 at 02:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dongkook stock traded at KRW 23,000 on October 7, 2026, while IBK set a KRW 30,000 target. Overseas healthcare sales drive the latest earnings case.

Dongkook, KR7086450004, Illustration mit AI erstellt.

Dongkook stock (ISIN KR7086450004) was trading at KRW 23,000 on October 7, 2026 at 9:39 a.m. KST, up KRW 1,300 or 5.99 percent from the prior close. The company is using CPHI Worldwide 2026 in Milan to present its long-acting injection platform and expand international pharmaceutical partnerships.

CPHI platform reaches global buyers

According to DongKook Pharmaceutical in a September 22, 2026 release, the company is exhibiting at CPHI Worldwide 2026 from October 6 to October 8. Its DK-LADs platform uses microsphere technology for long-acting injections, and the company plans to highlight development and supply opportunities with overseas pharmaceutical partners.

The Milan event also gives Dongkook a commercial setting for its Lorelin Depot 11.25 mg product, for which the company said it would present phase 3 results. The event is part of the company's broader push to turn its manufacturing and drug-delivery capabilities into international licensing and supply opportunities.

Overseas cosmetics lift estimates

The latest analyst catalyst arrived on October 2, 2026. Seoul Economic Daily reported that IBK Investment & Securities maintained a Buy rating and a KRW 30,000 target price, based on expanding healthcare sales through cosmetics distribution in the United States and Japan.

IBK projected second-half revenue of KRW 547.5 billion, up 16.6 percent year over year, and operating profit of KRW 60.1 billion, up 22.5 percent. The healthcare segment, which includes cosmetics, was expected to represent 39.3 percent of full-year revenue, compared with 31.9 percent in 2023.

Quarterly growth meets a higher bar

ATS View lists second-quarter 2026 revenue at KRW 258.9 billion, 10.9 percent above the year-earlier quarter, with operating profit of KRW 26.1 billion and net income of KRW 17.2 billion. The figures show that the overseas cosmetics thesis is being measured against an already growing base.

The market capitalization was KRW 1.0 trillion on October 7, 2026. The intraday price stood 26.4 percent below the 52-week high of KRW 31,250, leaving the next test tied to whether overseas distribution converts the analyst projections into reported margins.

Dongkook stock trades below yearly high

On KOSDAQ, Dongkook stock was trading at KRW 23,000 on October 7, 2026 at 9:39 a.m. KST, with an intraday range of KRW 22,050 to KRW 23,650. The 52-week range was KRW 16,260 to KRW 31,250.